Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

digital therapy

National Institute for Health and Care Excellence NICE logo

NICE calls for greater statin prescribing in wake of Lipitor generics

Wants more use of the drugs to help prevent cardiovascular disease

- PMLiVE

Shire’s ADHD drug fails in depression trial

Company drops Vyvanse for use in major depressive disorder

National Institute for Health and Care Excellence NICE logo

NICE reviews lung cancer drug guidance

Consults on availability of Roche's Tarceva and AZ's Iressa on NHS

- PMLiVE

Servier expands breast cancer partnership

Will build on deal with French cancer research centre Curie-Cancer

- PMLiVE

NICE backs Astellas’ Xtandi in prostate cancer

But company criticises restrictions imposed by HTA body for England

- PMLiVE

NICE set to extend MabThera recommendation

Says Roche’s drug can be used on NHS to treat two serious forms of vasculitis

- PMLiVE

NICE recommends Sanofi’s oral MS drug

Aubagio backed for NHS use in England and Wales

- PMLiVE

First Cymbalta generics approved in the US

Lilly prepares for onslaught of competition for antidepressant

- PMLiVE

Sanofi’s Aubagio backed by NICE

Oral MS drug recommended for NHS use in England and Wales

- PMLiVE

Lilly depression drug fails late-stage trials

Will not pursue edivoxetine as an add-on treatment for depression

National Institute for Health and Care Excellence NICE logo

NICE wants more info on Genzyme’s MS drug

UK health guidance body turns down Lemtrada in draft guidance

National Institute for Health and Care Excellence NICE logo

NICE backs two eye treatments

Novartis’ Lucentis and Alimera’s Iluvien received green light for NHS use

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links